13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q1 2023 · Filed February 14, 2023 · Accession 0001012975-23-000091
Total Value
$390.4M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | DENALI THERAPEUTICS, INC. | DNLI | 3,668,749 | $102.0M | 26.13% |
| 2 | KARUNA THERAPEUTICS, INC. | 48576A100 | 512,872 | $100.8M | 25.81% |
| 3 | EQRX, INC. | 26886C107 | 36,335,375 | $89.4M | 22.89% |
| 4 | ERASCA, INC. | ERAS | 11,055,554 | $47.6M | 12.20% |
| 5 | VERVE THERAPEUTICS, INC. | 92539P101 | 2,008,809 | $38.9M | 9.96% |
| 6 | SINGULAR GENOMICS SYSTEMS, INC. | 82933R100 | 3,798,926 | $7.6M | 1.96% |
| 7 | UNITY BIOTECHNOLOGY, INC. | UNTCW | 1,004,817 | $2.8M | 0.71% |
| 8 | METACRINE, INC. | 59101E103 | 2,940,503 | $1.3M | 0.34% |